Krystal Biotech (KRYS) Operating Income (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Operating Income of $58.4 million for Q2 2026, up 48.27% year-over-year from $39.4 million in Q2 2025, and up 8.81% on a QoQ basis from $53.7 million in Q1 2026.
Krystal Biotech (KRYS) Operating Income (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Operating Income for 11 years, with the latest figure at $58.4 million in Q2 2026.
- Operating Income for Q2 2026 came in at $58.4 million, up 48.27% year-over-year; the trailing twelve-month figure through Jun 2026 was $197.8 million (up 41.76% YoY), and the FY2025 annual result was $161.3 million, up 145.32% from the prior year.
- Operating Income rose to $58.4 million in Q2 2026, from $53.7 million in the prior quarter.
- Over five years, Operating Income peaked at $58.4 million in Q2 2026 and troughed at -$50.2 million in Q1 2022.
- A 5-year average of $4.7 million and a median of $5.9 million in 2023 frame the typical range for Operating Income.
- The widest annual swing landed in 2022, when Operating Income plunged 249.91%; it then surged 1173.86% in 2024.
- A 5-year view of Operating Income shows it stood at -$34.8 million in 2022, then soared by 109.34% to $3.2 million in 2023, then surged by 1173.86% to $41.4 million in 2024, then gained by 7.0% to $44.3 million in 2025, then jumped by 31.96% to $58.4 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were $58.4 million in Q2 2026, $53.7 million in Q1 2026, and $44.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 58.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.42 Mn |
| Mar 31, 2026 | 53.69 Mn |
| Dec 31, 2025 | 44.27 Mn |
| Sep 30, 2025 | 41.37 Mn |
| Jun 30, 2025 | 39.31 Mn |
| Mar 31, 2025 | 36.25 Mn |
| Dec 31, 2024 | 41.38 Mn |
| Sep 30, 2024 | 22.47 Mn |
| Jun 30, 2024 | 8.57 Mn |
| Mar 31, 2024 | -6.68 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Sep 30, 2023 | -25.99 Mn |
| Jun 30, 2023 | -38.05 Mn |
| Mar 31, 2023 | -48.82 Mn |
| Dec 31, 2022 | -34.77 Mn |
| Sep 30, 2022 | -31.45 Mn |
| Jun 30, 2022 | -28.75 Mn |
| Mar 31, 2022 | -50.22 Mn |
| Dec 31, 2021 | -21.88 Mn |
| Sep 30, 2021 | -15.65 Mn |